↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Pichat, P.; Bergis, O.; Terranova, J.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C. i dr.. (2007). „SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia”. Neuropsychopharmacology32 (1): 17–34. DOI:10.1038/sj.npp.1301188. PMID16936709.
↑Biton, B.; Bergis, O.; Galli, F.; Nedelec, A.; Lochead, A.; Jegham, S.; Godet, D.; Lanneau, C. i dr.. (2007). „SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile”. Neuropsychopharmacology32 (1): 1–16. DOI:10.1038/sj.npp.1301189. PMID17019409.
↑Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M. (2008). „Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711”. Biological Psychiatry63 (1): 92–97. DOI:10.1016/j.biopsych.2007.04.034. PMID17601496.
↑Barak, S.; Arad, M.; De Levie, A.; Black, M.; Griebel, G.; Weiner, I. (2009). „Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia”. Neuropsychopharmacology34 (7): 1753–1763. DOI:10.1038/npp.2008.232. PMID19158670.
